Pfizer (PFE) 2025 — COVID Revenue Collapsed, $67B Goodwill from Seagen

Grade: F — Major Red Flags

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-26) + Yahoo Finance

Auditor: KPMG LLP — Clean opinion (served since at least 1942)

Fiscal Year: 2025 (ended December 31, 2025)

One-line verdict: Pfizer's books are honestly prepared — KPMG gave an unqualified opinion and the M-Score is clean at -2.52. The F grade comes from two structural facts the screening engine cannot ignore: $125B in goodwill and intangibles representing 145% of equity, and $13.6B in cash covering only 21% of $64B in total debt. These are the permanent scars of buying growth at the top of a once-in-a-century revenue cycle. COVID revenue collapsed from $56.7B at peak (2022) to $6.7B in 2025. The $43B Seagen acquisition loaded the balance sheet with $71.3B in goodwill. GAAP EPS of $1.36 while the company pays $1.72/share in dividends — distributing more than it earns. And products with $22.7B in combined revenue face patent expiration between 2026 and 2028. This is a company running a race between its aging portfolio and its pipeline, and the financial statements tell you the margin for error is razor-thin.

The COVID Hangover: From $101B to $63B

This is the defining feature of Pfizer's financial statements. The 10-K's consolidated income statement tells the story:

Revenue declined 2% in 2025. The 10-K's revenue bridge explains why: "Worldwide declines from Paxlovid ($3,346M)" and "Worldwide declines from Comirnaty ($1,051M)" — a combined $4.4B decline in COVID products — partially offset by growth in Vyndaqel, Eliquis, Padcev, and other products.

The COVID product collapse in detail:

The 10-K states: "In 2025, due to seasonality of demand for COVID-19 vaccinations, the majority of our global revenues for Comirnaty were recorded in the fourth quarter." Paxlovid's decline is described as driven by "lower COVID-19 infections across U.S. and international markets and lower international government purchases."

The Product Portfolio: Revenue Concentration

The 10-K provides detailed revenue for key products:

Top 3 products (Eliquis, Prevnar, Vyndaqel) generate $20.9B — 33% of total revenue. The IRA is explicitly cited by the 10-K as impacting multiple products: "the impact of higher manufacturer discounts resulting from the IRA Medicare Part D Redesign" appears repeatedly for Ibrance, Xtandi, Xeljanz, and others. Management warns: "IRA Medicare Part D Redesign...negatively impacted our 2025 revenues by approximately $1 billion."

Balance Sheet: $125B in Goodwill + Intangibles, $64B in Debt

The screening engine flags this as a FAIL: "Goodwill+Intangibles $125.0B = 145% of equity. Over 50%."

The 10-K's goodwill note shows the build-up:

The 10-K states: "Additions in 2025 primarily represent our acquisition of Metsera" ($8B obesity/cardiometabolic company, adding $2.2B goodwill). 2024 additions were "primarily measurement period adjustments related to our acquisition of Seagen."

Critically: "We completed the re-allocation during the first quarter of 2025 and concluded that none of our goodwill was impaired." But consider the math: Seagen's two flagship products — Padcev ($1.9B, +22%) and Adcetris ($907M, -17%) — generated $2.8B combined on a $43B acquisition price. Even at pharma margins, payback takes decades.

The $53.7B in intangible assets includes substantial in-process R&D (IPR&D) — drugs still in development. The 10-K shows $1,613M in "acquired in-process research and development expenses" charged in 2025 (primarily from the Metsera acquisition and licensing deals with 3SBio and YaoPharma). These are inherently high-risk assets: if clinical trials fail, they get written to zero.

Debt

The screening engine flags: "Cash $13.6B covers only 21% of debt $64.0B." This is a FAIL on C4.

Context: Debt/EBITDA is 3.8x and interest coverage is 6.5x — elevated for pharma but not critical. Credit rating is A2/A stable. Cash declined $6.9B year-over-year (from $20.5B to $13.6B), largely due to Metsera acquisition costs, dividend payments, and debt service.

Profitability: GAAP vs. Adjusted — A $10B Gap

From the 10-K income statement, the major cost items:

The 10-K explains the cost of sales decline: "primarily due to a favorable change in sales mix of $1.4 billion driven by lower sales of Comirnaty and Paxlovid" and "a decrease of $633 million due to lower amortization from the step-up of acquired inventory."

Gross margin improved from 58% to 74% — but this is the COVID hangover fading. In 2023, massive COVID inventory write-downs depressed gross margin. The 10-K confirms the improvement is largely mix-driven, not from pricing power.

"Other deductions, net" surged from $4.4B to $6.7B (+53%). This line warrants scrutiny — it includes asset impairments, pension costs, and various one-time items.

The Patent Cliff: 2026-2030

The 10-K explicitly warns: "We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years. In 2026, the impact from patent-based or regulatory exclusivity expiries is expected to be $1.5 billion."

Combined revenue at risk: $22.7B — 36% of total revenue within three years.

The 10-K adds that CMS has selected Eliquis, Ibrance, and Xtandi for the Medicare Drug Price Negotiation Program with Maximum Fair Prices effective 2026-2028, creating additional pricing pressure before patent expiration even hits.

The offset: later-cycle drugs have longer patent protection (Prevnar 20, Padcev, Lorbrena, Nurtec, Abrysvo). But these must grow fast enough to replace what's evaporating.

Cash Flow: Covering Dividends, Barely

CFFO/NI of 1.51 is healthy — the screening engine confirms: "CFFO/NI = 1.51. Profits backed by cash." FCF of $9.1B is solid in isolation. But dividends of $9.8B consume 108% of free cash flow.

At $1.72/share annually across 5.7B shares, the dividend costs roughly $9.8B per year. In 2025, Pfizer paid out more in dividends than its free cash flow. The company is effectively borrowing to maintain its dividend — or at minimum, not deleveraging because of the dividend obligation.

No shares were repurchased in 2025 despite $3.3B remaining on the buyback authorization. That tells you management knows the balance sheet is stretched.

IRA and Government Pricing Impact

The 10-K discloses a significant new development: "In September 2025, we announced an agreement with the Trump Administration in which we voluntarily agreed to implement measures designed to make certain drug prices for U.S. patients more comparable to those in other developed countries."

The agreement provides a "three-year grace period during which time our products will not face Section 232 tariffs, provided the Company further invests in manufacturing in the U.S."

Additionally, Pfizer is "participating in the TrumpRx.gov platform, which allows U.S. patients to purchase certain medicines at significant discounts to current retail prices, where the large majority of the Company's primary care treatments and some select specialty brands will be offered at savings that will range as high as 85% and on average 50%."

Product revenue deductions totaled $36.4B in 2025 (vs $33.9B in 2024), including $14.0B in chargebacks, $7.0B in performance-based rebates, and $4.5B in Medicare rebates. These deductions represent 58% of gross product revenues — meaning for every dollar in gross revenue, Pfizer keeps only 42 cents after rebates and discounts.

Auditor's Critical Audit Matters

KPMG identified two Critical Audit Matters:

1. Uncertain Tax Positions — Given Pfizer's global operations, the evaluation of tax positions involves "a high degree of estimation uncertainty" and required "tax and valuation professionals with specialized skills and knowledge."

2. Product Liability and Other Product-Related Litigation — The 10-K notes Pfizer is "involved in product liability and other product-related litigation, which can include personal injury, consumer fraud, off-label promotion, securities, antitrust and breach of contract claims." KPMG found this required "challenging auditor judgment to evaluate the Company's judgments about future events and uncertainties."

The 18-Point Screening

Revenue Quality

Expense Quality

Cash Flow Quality

Balance Sheet

Acquisition Risk

Beneish M-Score

M-Score components: DSRI 1.053, GMI 0.968, AQI 1.034, SGI 0.984, DEPI 1.085, SGAI 0.952, TATA -0.019, LVGI 1.006. All within normal ranges. Notably, SGI < 1.0 (revenue declining) and SGAI < 1.0 (SG&A declining faster than revenue), consistent with a cost-cutting company.

Additional Scores: F-Score probability of misstatement 0.60% (low). Altman Z-Score 3.06 (safe zone, driven by the strong retained earnings and equity base).

Key Risks from the 10-K

1. Patent Cliff (2026-2030) — The 10-K states directly: "We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030...with the rate of the reduction of revenues expected to significantly accelerate over the next few years." $22.7B in revenue at risk.

2. Government Pricing Pressure — CMS selected Eliquis for the Medicare Drug Price Negotiation Program with Maximum Fair Price effective January 1, 2026. Ibrance and Xtandi selected for 2027 and Xeljanz for 2028. The IRA Medicare Part D Redesign "negatively impacted our 2025 revenues by approximately $1 billion."

3. Seagen Integration Risk — The $43B acquisition generated $71.3B in total goodwill. If Seagen pipeline drugs fail in trials, goodwill impairment becomes inevitable. Adcetris is already declining (-17%) due to competitive pressure.

4. Tariff Uncertainty — The 10-K references the September 2025 Trump Administration agreement and notes: "We are currently evaluating the impact of the U.S. Supreme Court's February 2026 decision relating to executive authority to impose tariffs under IEEPA." Section 232 investigations of pharmaceuticals remain ongoing.

5. COVID Franchise Decline — Comirnaty faces "continuous decline in vaccination rates due to additional changes in vaccination recommendations." Paxlovid still operates under an EUA and has not received full FDA approval.

6. Product Liability Litigation — KPMG flagged this as a Critical Audit Matter. The 10-K states: "Certain of these pending product and other product-related legal proceedings could result in losses that could be substantial."

Summary

Grade: F. Clean accounting, but the balance sheet carries enormous structural risk.

The F grade is mechanical: two hard fails on the 18-point screening — goodwill at 145% of equity and cash covering only 21% of debt. These are not signs of fraud. They are the consequences of Pfizer's acquisition strategy: $43B for Seagen, $8B for Metsera, all financed with debt, all piled onto a balance sheet that was already carrying $35B in legacy debt.

The M-Score of -2.52 is clean. KPMG gave an unqualified opinion. Cash flow quality is strong (CFFO/NI of 1.51, accruals ratio of -1.9%). There is no evidence of accounting manipulation. The financial statements are honestly prepared.

The business risks are what drive the grade: a patent cliff threatening $22.7B in revenue over the next three years, a dividend that consumes 108% of free cash flow, government pricing pressure from the IRA and the Trump Administration's pricing agreement, and $125B in goodwill and intangibles that depend on pipeline success to justify their carrying values.

Buying Pfizer is betting that Padcev, Lorbrena, Abrysvo, Nurtec, Vyndaqel, and the Metsera obesity pipeline can collectively replace $20B+ in revenue that's about to evaporate from patent expirations and COVID franchise decline. The financial statements can't tell you if that bet will pay off. They can tell you the margin for error is virtually zero: every dollar of free cash flow is already spoken for by the dividend, debt has risen to $64B, and the single largest product (Eliquis at $8.0B) faces generic entry within two years.

**Disclaimer**: This report is based on Pfizer's 2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

**About EarningsGrade**: We screen earnings reports for financial red flags. Grade F means major red flags were detected that require serious investigation before proceeding.